- In January 2024, Medtronic received CE Mark approval for its next-generation leadless devices, Micra AV2 and Micra VR2. These devices will now be commercially available across the European region
- In July 2023, Abbott’s AVEIR DR, the first dual-chamber leadless pacemaker, gained FDA approval. This innovative device addresses abnormal or slow heart rhythms, providing advanced therapy options for millions in the U.S
- In May 2023, the FDA approved Medtronic’s Micra AV2 and Micra VR2 leadless pacemakers, offering enhanced battery life and simplified programming to expand patient access to this therapy
- In February 2022, Abbott achieved a significant milestone in leadless pacing technology with the first patient receiving the Aveir dual-chamber leadless pacemaker as part of the AVEIR DR i2i pivotal clinical trial
- In January 2022, Medtronic obtained approval from Japan's Ministry of Health, Labor, and Welfare for the Micra AV Transcatheter Pacing System (TPS). The product was launched in June 2022 after securing reimbursement
